Recent Updates
Recently added Catalysts
IMMP

Prima BioMed Receives A$1.3 Million Tax Refund from French Government

Key Takeaway: Prima BioMed Receives A$1.3 Million Tax Refund from French Government

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Full Press Release Details

Prima BioMed Receives A$1.3 Million Tax Refund from French Government.
Last updated: Aug 14, 2017